OncoVista to sell AdnaGen unit for up to $65M

OncoVista Innovative Therapies has divested its majority holding of its German subsidiary AdnaGen AG. As a result, the company will receive as much as $65 million in cash, enabling it to develop additional non-toxic and more efficacious treatments for cancer.

"The importance of this transaction should not be underestimated by our shareholders," says Alexander Weis, president and CEO of OncoVista. "The proceeds will allow the Company to not only develop the current anticancer drugs in our portfolio more quickly, but to continue to build and enhance our drug portfolio to the benefit of shareholders and more importantly, patients. I would also like to acknowledge HealthPro Bioventures LLC, which was instrumental in working with OncoVista to structure and negotiate this meaningful transaction for our company."

Texas-based OncoVista specializes in identifying specific biomarkers in the bloodstream carried by circulating tumor cells to detect metastatic tumors, thus allowing an oncologist to develop personalized cancer treatments.

- get the OncoVista release

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.